Your institution may have access to this item. Find your institution then sign in to continue.
Title
PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone.
Authors
Zinman, Bernard
Abstract
Examines the metabolic effects of rosiglitazone, a proliferator-activated receptor-gamma agonist used in the treatment of type 2 diabetes. Glycemic control; Insulin sensitivity and Beta-cell function; Abdominal obesity; Hypertension; Dyslipidemia.